Here are four things to know:
1. OralDNA Labs plans to use the acquisition to commercialize a new point-of-care molecular diagnostics system capable of providing test results from saliva or swabs in 10 minutes or less.
2. The company’s platform includes a four-channel system and test cartridges designed to enhance accuracy and speed of chairside diagnostics
3. OralDNA Labs’ initial development has focused on the oral microbiome to help dentists diagnose and treat periodontal disease and other oral systemic illnesses.
4. The platform and assays that are currently under development have not received FDA clearance and are not for sale.
At the Becker's 5th Annual Future of Dentistry Roundtable, taking place November 12–14 in Chicago, dental leaders and executives will gain insights into emerging technologies, practice growth strategies and the evolving landscape of dental care delivery, with a focus on innovation, patient experience and operational excellence. Apply for complimentary registration now.
